Mark J. Ratain | Researchain

Archive Network Publication Hotspot Collaboration

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Mark J. Ratain is active.

Explore More

Publication

Featured researches published by Mark J. Ratain.

Archive | 2004

Systemically Administered Drugs

Reginald B. Ewesuedo; Mark J. Ratain

Although the use of drugs in the management of cancer has made a significant impact on the outcome of most types of malignancies, one of the lingering challenges in cancer therapeutics is how to influence the outcome of cancer treatment by optimal and careful application of anticancer drugs. Addressing this challenge requires the adoption of treatment strategies that employ sound pharmacologic principles in the use of anticancer agents.

Clinical Cancer Research | 2002

Phase I Clinical and Pharmacokinetic Study of Protein Kinase C-α Antisense Oligonucleotide ISIS 3521 Administered in Combination with 5-Fluorouracil and Leucovorin in Patients with Advanced Cancer

Sridhar Mani; Charles M. Rudin; Katie Kunkel; Jon T. Holmlund; Richard S. Geary; Hedy L. Kindler; F. Andrew Dorr; Mark J. Ratain

Archive | 2002

Methods for detection of promoter polymorphism in a UGT gene promoter

Anna Di Rienzo; Lalitha Iyer; Mark J. Ratain

Archive | 2005

Methods and compositions relating to the pharmacogenetics of abcc2, ugt1a1, and/or slc01b1 gene variants

Mark J. Ratain; Federico Innocenti; Deanna L. Kroetz; Samir Undevia; Tan D. Nguyen; Wanqing Liu

Journal of Clinical Oncology | 2005

Irinotecan (CPT-11) pharmacokinetics (PK) and neutropenia: interaction among UGT1A1 and transporter genes

Federico Innocenti; Samir D. Undevia; Gary L. Rosner; L. Xiao; Wanqing Liu; Peixian Chen; Soma Das; Jacqueline Ramírez; Deanna L. Kroetz; Mark J. Ratain

Journal of Clinical Oncology | 2006

1249G>A polymorphism of ABCC2 (MRP2) is associated with altered gene expression in human liver

Deanna L. Kroetz; Wanqing Liu; T. D. Nguyen; B. M. Zwecker; Jacqueline Ramírez; Federico Innocenti; Mark J. Ratain

Journal of Clinical Oncology | 2006

A prospective pharmacogenomic (PG), pharmacodynamic (PD), and pharmacokinetic (PK) study of determinants of erlotinib toxicity

Charles M. Rudin; Apurva A. Desai; Linda Janisch; Michael A. Carducci; Theodore Karrison; Wanqing Liu; Gini F. Fleming; Jacqueline Ramírez; Federico Innocenti; Mark J. Ratain

Journal of Clinical Oncology | 2004

Haplotype analysis of UGT1A1 and UGT1A9 gene polymorphisms related to the glucuronidation of SN-38, the active metabolite of irinotecan

W. Liu; Federico Innocenti; P. X. Chen; A. Desai; Carrie Grimsley; A. Di Rienzo; Soma Das; Mark J. Ratain

Journal of Clinical Oncology | 2010

Effect of coadministration of statins on neutropenia in a phase I genotype-directed dose-escalation study of irinotecan.

Federico Innocenti; Theodore Karrison; Jacqueline Ramírez; Linda Janisch; W. Zhang; Kehua Wu; Mark J. Ratain

ASCO 2001: American Society of Clinical Oncology 37th Annual Meeting | 2001

Two schedules of oral topotecan for Myelodysplastic Syndrome (MDS)-CALGB Study 19803

David L. Grinblatt; Daohai Yu; Cheryl Klein; Helen Kastrissios; Antonius A. Miller; Vera Hars; Donna Hollis; Gary L. Rosner; Bayard L. Powell; Mark J. Ratain; Richard A. Larson

Explore More